2014

DaVita business units DaVita Clinical Research, HealthCare Partners Clinical Research to merge

Monday, December 15, 2014

DaVita HealthCare Partners, a U.S. innovative healthcare community, has announced that two of its business units, DaVita Clinical Research (DCR) and HealthCare Partners Clinical Research, will merge capabilities to further expand its clinical research and data analytics services, specifically in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD), as well as primary care and chronic disease patients treated in an integrated care organization.

[Read More]

Anergis starts phase II trial with birch pollen allergy vaccine AllerT

Monday, December 15, 2014

Anergis, a Swiss-based company developing proprietary ultra-fast allergy vaccines, has begun a phase II trial designed to finalize the dose selection for the phase III study of AllerT. AllerT is Anergis´ lead vaccine against birch pollen allergy that originated from the company´s proprietary Contiguous Overlapping Peptide (COP) platform. COPs are pharmaceutical-grade, long-peptide immunotherapeutics designed for an ultra-fast, safe and long-lasting treatment of allergy patients.

[Read More]

CRF Health boosts leadership team with new appointments

Monday, December 15, 2014

CRF Health, a Plymouth Meeting, Pa.-based global provider of eCOA solutions for the life sciences Industry, has announced two new additions to the company’s executive leadership team as the organization continues to invest in a deeper and broader management structure to position the business for future growth.

[Read More]

Senators introduce bill for streamlined pathway to approval for antibiotics

Friday, December 12, 2014

U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT) have introduced a bill to create a new drug approval pathway to streamline access and encourage innovation and development of potentially lifesaving antibiotic drugs for patients, particularly Veterans who have encountered antibiotic-resistant bacteria while overseas.

[Read More]